Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$339 Mln
P/E Ratio
--
P/B Ratio
1.39
Industry P/E
--
Debt to Equity
0.01
ROE
-0.55 %
ROCE
-53.2 %
Div. Yield
0 %
Book Value
3.47
EPS
-1.83
CFO
$-330.92 Mln
EBITDA
$-343.00 Mln
Net Profit
$-413.97 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Oric Pharmaceuticals Inc (ORIC)
| -36.00 | -26.53 | -47.67 | -40.77 | 11.46 | -- | -- |
|
BSE Sensex*
| 2.05 | 3.83 | 4.35 | 8.29 | 11.76 | 20.17 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Oric Pharmaceuticals Inc (ORIC)
| -12.19 | 56.20 | -59.93 | -56.57 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.78 | 9,808.03 | 20.22 | 23.13 | |
| 290.25 | 8,956.09 | 22.08 | 58.42 | |
| 26.54 | 9,559.25 | -- | -28.77 | |
| 103.22 | 10,030.35 | 30.81 | 14.16 |
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a... brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Address: 240 East Grand Avenue, South San Francisco, CA, United States, 94080 Read more
Co-Founder, Independent Chairman & Member of Scientific Advisory Board
Dr. Richard A. Heyman Ph.D.
Co-Founder, Independent Chairman & Member of Scientific Advisory Board
Dr. Richard A. Heyman Ph.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Oric Pharmaceuticals Inc (ORIC) stood at $ 274 Mln as on 31-Dec-24
The share price of Oric Pharmaceuticals Inc (ORIC) is $5.17 (NASDAQ) as of 23-Apr-2025 16:00 EDT. Oric Pharmaceuticals Inc (ORIC) has given a return of 11.46% in the last 3 years.
Oric Pharmaceuticals Inc (ORIC) has a market capitalisation of $ 339 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Oric Pharmaceuticals Inc (ORIC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Oric Pharmaceuticals Inc (ORIC) and enter the required number of quantities and click on buy to purchase the shares of Oric Pharmaceuticals Inc (ORIC).
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Address: 240 East Grand Avenue, South San Francisco, CA, United States, 94080
The CEO & director of Dr. Richard A. Heyman Ph.D.. is Oric Pharmaceuticals Inc (ORIC), and CFO & Sr. VP is Dr. Richard A. Heyman Ph.D..
There is no promoter pledging in Oric Pharmaceuticals Inc (ORIC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Oric Pharmaceuticals Inc (ORIC) | Ratios |
|---|---|
|
Return on equity(%)
|
-54.73
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Oric Pharmaceuticals Inc (ORIC) was $0 Mln.
$-0.06
(
